Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806
Latest Information Update: 06 May 2021
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Peyronie's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms IMPRESS-ED
- Sponsors Auxilium Pharmaceuticals; Endo International; Endo Pharmaceuticals
- 01 Apr 2021 Results published in the International Journal of Impotence Research
- 04 Sep 2020 Results of post hoc analysis from NCT02298829, NCT01221597, NCT01221623, NCT01243411 and NCT01685437 determoning the long-term (5 year) efficacy and safety profile of CCH in men subgrouped by the degree of penile plaque calcification prior to treatment, published in the Urology
- 21 Jun 2018 This trial has been completed in Sweden.(End date: 2018-03-29)